Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Investigators hypothesize that combination of ATLG with PTCy in matched or mismatched
unrelated hematopoietic stem cell transplantation will reduce acute and chronic GVHD
incidence. Furthermore it will allow shortening of the length of post-transplantation
immunosuppression with calcineurin inhibitor (CNI) administration (currently administrated in
addition to ATG as GVHD prophylaxis in daily common practice)